

4 May 2018

Company Announcements Office  
Australian Securities Exchange

## **Nanosonics receives Health Canada clearance for the latest generation of trophon – trophon<sup>®</sup>2**

Further to the announcement made by Nanosonics Limited (ASX:NAN) on 27 April 2018 regarding the US FDA clearance for its 2<sup>nd</sup> generation trophon platform device – trophon2, Nanosonics today announced receipt of the Medical Device Licence from Health Canada for the trophon2 system.

“This excellent news enables Nanosonics to launch trophon2 both in the US and Canada during the first quarter of the 2019 financial year. Canada is an important market, representing an opportunity for trophon similar to Australia. Importantly, Canada has strong fundamentals for adoption with High Level Disinfection guidelines already in place. The new functionality of trophon2 places Nanosonics in a good position to establish trophon as standard of care in the Canadian market,” said Michael Kavanagh, Nanosonics’ Chief Executive Officer and President.

**Michael Kavanagh**  
**CEO / President**

For more information please contact:  
Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

### **About Nanosonics:**

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection, improving the safety of patients, clinics, their staff and the environment. The Company is an innovator in infection prevention and owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of global markets that aim to deliver improved standards of care. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit [www.nanosonics.com.au](http://www.nanosonics.com.au)